“According to a new report published by Introspective Market Research, Allergy Immunotherapy Market by Treatment Type, Allergy Type, and Distribution Channel, The Global Allergy Immunotherapy Market Size Was Valued at USD 2.26 Billion in 2024 and is Projected to Reach USD 5.66 Billion by 2035, Growing at a CAGR of 8.70%.”

Allergy Immunotherapy (AIT), often referred to as allergy shots or allergy vaccines, is a preventive treatment for allergic reactions to substances such as grass pollens, house dust mites, and insect venom. Unlike traditional anti-allergy medications like antihistamines and nasal sprays, which only mask symptoms, AIT works by modifying the body's immune system. It involves administering gradually increasing doses of the specific allergen to which a person is sensitive, which causes the immune system to become less reactive over time, effectively building tolerance and providing long-term relief.

AIT offers significant advantages over conventional, symptomatic treatments by targeting the underlying cause of the allergy, potentially preventing the development of new allergies and reducing the progression of allergic asthma. The two main forms of AIT are Subcutaneous Immunotherapy (SCIT), delivered via injections under a doctor's supervision, and Sublingual Immunotherapy (SLIT), available as tablets or drops placed under the tongue for at-home use. These treatments are primarily used in the major industries of allergic rhinitis, allergic asthma, and insect venom hypersensitivity, offering patients a path to reduced reliance on daily medication and a substantially improved quality of life. The increasing acceptance of convenient SLIT options is further expanding the patient pool suitable for this desensitization approach.

Market Segmentation:

The Allergy Immunotherapy Market is segmented into Treatment Type, Allergy Type, and Distribution Channel. By Treatment Type, the market is categorized into (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT)). By Allergy Type, the market is categorized into (Allergic Rhinitis, Allergic Asthma, Others). By Distribution Channel, the market is categorized into (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies).

Growth Driver:

The primary factor propelling the growth of the Allergy Immunotherapy Market is the significantly rising global prevalence of allergic disorders. Environmental factors such as escalating pollution levels, climate change, and changes in lifestyle and dietary habits have contributed to a worldwide surge in conditions like allergic rhinitis, allergic asthma, and food allergies. Recent estimates indicate that approximately 30-40% of the global population suffers from some form of allergy, creating a massive and growing patient pool. This increasing burden of chronic allergic conditions necessitates effective, long-term therapeutic solutions, directly increasing the demand for Allergy Immunotherapy, which offers disease-modifying benefits and sustained relief, unlike short-term symptomatic treatments.

Market Opportunity:

A key market opportunity for the Allergy Immunotherapy Market lies in the advancements and increasing adoption of personalized medicine and innovative delivery platforms. The shift towards more targeted and patient-centric therapies, particularly in sublingual immunotherapy (SLIT), presents a lucrative avenue for market expansion. The development of customized treatment plans based on a patient's specific allergen sensitivities, along with the launch of new products such as recombinant allergens and peptide-based immunotherapies, promises greater efficacy and a better safety profile. Furthermore, the integration of digital health technologies for remote patient monitoring and consultation is enhancing treatment adherence and accessibility, particularly in emerging and underserved markets, positioning these innovative approaches as significant future growth catalysts.

Detailed Segmentation:

Line below: The Allergy Immunotherapy Market is segmented on the basis of Treatment Type, Allergy Type, and Distribution Channel.

Treatment Type

The Treatment Type segment is further classified into Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT). Among these, the Subcutaneous Immunotherapy (SCIT) sub-segment accounted for the highest market share in 2024. This dominance is attributed to SCIT's long-standing history as the gold standard for allergy treatment, its high efficacy, and its ability to treat a broad range of allergens, including pollen, dust mites, and insect venom. Healthcare professionals are highly familiar with SCIT protocols, and it is often the first-line preference for severe cases, such as venom-induced anaphylaxis, as it is known to induce a strong, long-lasting immune response. Its well-established clinical track record and broad coverage continue to ensure its leading position in the overall AIT market.

Allergy Type

The Allergy Type segment is further classified into Allergic Rhinitis, Allergic Asthma, and Others. Among these, the Allergic Rhinitis sub-segment accounted for the highest market share in 2024. Allergic Rhinitis, characterized by symptoms like sneezing, nasal congestion, and itchy eyes, affects a substantial portion of the global population, with prevalence rates estimated between 10% and 30% of adults. This high global incidence makes it the single largest indication for AIT treatment. The established effectiveness of both SCIT and SLIT in providing long-term symptomatic relief and disease modification for this condition drives its dominant market share, as patients seek enduring solutions beyond daily medication for their persistent symptoms.

Some of The Leading/Active Market Players Are-

·         Stallergenes Greer (UK/France)

·         ALK-Abelló A/S (Denmark)

·         Allergy Therapeutics (UK)

·         HAL Allergy Group (Netherlands)

·         LETI Pharma (Spain)

·         Merck KGaA (Germany)

·         DBV Technologies SA (France)

·         Aimmune Therapeutics (US)

·         Jubilant HollisterStier LLC (US)

·         Allergopharma GmbH & Co. KG (Germany)

·         Biomay AG (Austria)

·         Circassia Pharmaceuticals Inc. (UK)

·         Anergis (Switzerland)

·         HollisterStier Allergy (US)

and other active players.

Key Industry Developments

In January 2023, ALK received U.S. FDA approval for the use of its house dust mite allergen extract sublingual tablet, ODACTRA, for the treatment of house dust mite-induced allergic rhinitis.

This regulatory milestone significantly bolstered the market for Sublingual Immunotherapy (SLIT) tablets in the crucial North American region. The FDA approval provided greater credibility and insurance coverage for an at-home, patient-friendly alternative to traditional allergy shots, expanding treatment options for a common perennial allergy and improving patient adherence.

In 2024, Stallergenes Greer published the EfficAPSI real-world study in The Lancet Regional Health – Europe, confirming the positive impact of its liquid SLIT on the onset and progression of allergic asthma in patients with allergic rhinitis.

This study provided robust real-world evidence of the long-term, disease-modifying benefits of liquid SLIT beyond mere symptom control. The confirmation that SLIT can help prevent the development or worsening of allergic asthma is a critical clinical finding, expected to drive broader recommendation and adoption of SLIT by healthcare professionals globally.

Key Findings of the Study

·         Dominant Segments: Subcutaneous Immunotherapy (SCIT) holds the largest share by treatment, while Allergic Rhinitis is the dominant allergy type.

·         Leading Regions: North America continues to dominate the market due to high allergy prevalence and advanced healthcare infrastructure.

·         Key Growth Drivers: The primary driver is the rising global incidence of various allergic disorders.

·         Market Trends: The increasing adoption of convenient Sublingual Immunotherapy (SLIT) tablets and drops is a significant market trend.

About Us

At Introspective Market Research Private Limited, we are a forward-thinking research consulting firm committed to driving growth in the Allergy Immunotherapy Market. With deep insights, strategic solutions, and holistic research, we empower businesses to achieve success and dominance in the global Allergy Immunotherapy Market industry.

More Info:- https://introspectivemarketresearch.com/reports/allergy-immunotherapy-market/

📞 Contact Us Introspective Market Research Pvt. Ltd.

 Phone: +91-91753-37569

 Email: sales@introspectivemarketresearch.com

Web: www.introspectivemarketresearch.com